Dear Dr. Brown:

Please refer to your supplemental biologics license application (sBLA) dated and received June 23, 2022, and your amendments, submitted under section 351(a) of the Public Health Service Act for Keytruda (pembrolizumab) injection.

This Prior Approval supplemental biologics application provides for revisions to the Prescribing Information to update the endometrial carcinoma indication and the corresponding information in DOSAGE AND ADMINISTRATION and CLINICAL STUDIES sections to reflect availability of the FDA-approved test, the VENTANA MMR RxDx Panel, for identifying patients with mismatch repair proficient (pMMR) advanced endometrial carcinoma.

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

WAIVER OF HIGHLIGHTS ½ PAGE LENGTH REQUIREMENT FOR HIGHLIGHTS

Please note that we have previously granted a waiver of the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of Prescribing Information.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit, via the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format, as described at
FDA.gov,\textsuperscript{1} that is identical to the enclosed labeling (text for the Prescribing Information and Medication Guide) and include the labeling changes proposed in any pending “Changes Being Effected” (CBE) supplements.

Information on submitting SPL files using eLIST may be found in the guidance for industry SPL Standard for Content of Labeling Technical Qs and As.\textsuperscript{2}

The SPL will be accessible via publicly available labeling repositories.

Also, within 14 days, amend all pending supplemental applications that include labeling changes for this BLA, including pending “Changes Being Effected” (CBE) supplements, for which the FDA has not yet issued an action letter, with the content of labeling [21 CFR 601.12(f)] in Microsoft Word format that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

**REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

**FULFILLMENT OF POSTMARKETING COMMITMENT**

We have received your submission dated June 23, 2022, reporting on the following postmarketing commitment listed in the September 17, 2019, approval letter for BLA 125514/S-065.

\section*{3700-4} Commitment to support the availability of an immunohistochemistry-based in vitro diagnostic device that is essential to the safe and effective use of the lenvatinib and pembrolizumab combination for patients with tumors that are mismatch repair proficient through an appropriate analytical and clinical validation study using clinical trial data that will support labeling.

\textsuperscript{1} http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm

\textsuperscript{2} We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database https://www.fda.gov/RegulatoryInformation/Guidances/default.htm.

U.S. Food and Drug Administration
Silver Spring, MD 20993
www.fda.gov

Reference ID: 5025590
We have reviewed your submission and conclude that the above commitment was fulfilled.

We remind you that there are postmarketing commitments listed in the September 17, 2019, approval letter that are still open.

**REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved BLA (in 21 CFR 600.80 and in 21 CFR 600.81).

If you have any questions, contact Jessica Kim, Regulatory Project Manager, at 240-402-0883 or Jessica.Kim1@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Laleh Amiri-Kordestani, MD
Director
Division of Oncology 1
Office of Oncologic Diseases
Center for Drug Evaluation and Research

ENCLOSURE(S):

- Content of Labeling
  - Prescribing Information
  - Medication Guide
This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

LALEH AMIRI KORDESTANI
08/05/2022 11:21:03 AM